Zosano Pharma Corp.Find Ratings Reports
ZOSANO PHARMA CORP's gross profit margin for the second quarter of its fiscal year 2021 has significantly decreased when compared to the same period a year ago. Even though it increased sales and net income significantly, the company was unable to grow at a faster pace than its subsector competitors. ZOSANO PHARMA CORP has strong liquidity. Currently, the Quick Ratio is 1.96 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 133.24% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY21||Q2 FY20|
|Net Sales ($mil)||0.19||0.0|
|Net Income ($mil)||-6.14||-7.9|
|Balance Sheet||Q2 FY21||Q2 FY20|
|Cash & Equiv. ($mil)||22.06||10.55|
|Total Assets ($mil)||60.85||47.71|
|Total Debt ($mil)||12.47||17.76|
|Profitability||Q2 FY21||Q2 FY20|
|Gross Profit Margin||-4009.57||0.0|
|Return on Assets||-51.06||-74.16|
|Return on Equity||-72.15||-191.65|
|Debt||Q2 FY21||Q2 FY20|
|Share Data||Q2 FY21||Q2 FY20|
|Shares outstanding (mil)||113.33||57.25|
|Div / share||0.0||0.0|
|Book value / share||0.38||0.32|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1035674.0||2263167.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.71 indicates a significant discount versus the S&P 500 average of 4.43 and a significant discount versus the subsector average of 9.95. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. The valuation analysis reveals that, ZOSANO PHARMA CORP seems to be trading at a premium to investment alternatives.
|ZSAN NM||Peers 80.14||ZSAN NM||Peers 42.50|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ZSAN's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ZSAN's P/CF is negative making the measure meaningless.
|ZSAN NM||Peers 68.42||ZSAN NA||Peers 0.57|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ZSAN's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ZSAN 1.71||Peers 9.95||ZSAN 76.26||Peers 168.96|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ZSAN is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ZSAN is expected to significantly trail its peers on the basis of its earnings growth rate.
|ZSAN 109.95||Peers 14.98||ZSAN NA||Peers 25.75|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ZSAN is trading at a significant premium to its subsector.
Neutral. Comparing a company's sales growth to its subsector helps to determine if the company is adding or losing market share.
The growth rate for ZSAN is not available.